Business Wire

Happiness Continues for Jonas Brothers Fans With an All New Concert Documentary Premiering Tomorrow, Friday April 24, 2020 Exclusively on Amazon Prime Video

Share

Happiness Continues: A Jonas Brothers Concert Film, which offers a behind the scenes look at the GRAMMY-nominated multiplatinum powerhouse trio Jonas Brothers on their sold-out “Happiness Begins” 2019 concert tour, will premiere tomorrow, Friday April 24, exclusively on Amazon Prime Video, in more than 200 countries and territories worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200423005868/en/

Happiness Continues: A Jonas Brothers Concert Film (Photo: Amazon Studios)

Happiness Continues: A Jonas Brothers Concert Film (Photo: Amazon Studios)

- Key art can be found here: LINK
- Watch Happiness Continues trailer HERE

Continuing the journey that began with last year’s Amazon Original documentary Chasing Happiness, Happiness Continues captures the band’s live concert experience and provides an exclusive look into the Jonas Brothers’ lives on the road, including performances of beloved hits like “Burnin’ Up,” “S.O.S.,” and “Year 3000,” and music from last year’s chart-topping “Happiness Begins” album, including their Billboard #1 smash “Sucker.” Happiness Continues gives viewers a front-row seat in fan-packed arenas in Miami, Vancouver, and Mexico City, as well as at the intimate Cobra Lounge in Chicago, in their first time performing there in 12 years. Happiness Continues gives fans a deeper look at how Nick, Joe, and Kevin navigate tour life while continuing to balance music, their relationship with one another, and their new families.

Happiness Continues is from Philymack and Amazon Studios in association with Polygram Entertainment and Federal Films, with executive producers Phil McIntyre, John Lloyd Taylor, Monte Lipman, Wendy Goldstein, and Baz Halpin. Happiness Continuesis directed by Anthony Mandler, and produced by Kim Bradshaw, Ned Doyle and Anthony Mandler, through Mandler’s production company Black Hand Cinema.

Following a six-year hiatus, Jonas Brothers took the world by storm in 2019 with the surprise release of their critically acclaimed and widely successful single "Sucker."The double-platinum single debuted at #1 on Billboard's Hot 100, becoming the first #1 for the band and the first #1 debut from a group this century. The band went on to release Chasing Happiness, an Amazon Original film documenting the brothers rise and return to music, before going on to deliver their third #1 album debut with the release of their platinum-selling album Happiness Begins (Republic Records). Throughout the year the band continued to soar with their sold-out “Happiness Begins Tour,” with over 1.2 million tickets sold.

JONAS BROTHERS SOCIAL HANDLES:
http://instagram.com/jonasbrothers
http://twitter.com/jonasbrothers
https://www.facebook.com/JonasBrothers
https://www.youtube.com/user/JonasBrothersMusic

AMAZON PRIME VIDEO SOCIAL HANDLES:
Hashtag: #HappinessContinues
Twitter: @PrimeVideo
Instagram/Facebook: @AmazonPrimeVideo

Happiness Continues is a global release and will be available exclusively on Prime Video in more than 200 countries and territories.

Customers who are not already Prime members can sign up for a free trial at www.amazon.com/prime.

For a list of all Prime Video compatible devices, visit www.amazon.com/howtostream.

FEDERAL FILMS:

Federal Films is a new division of Republic Records in strategic alliance with Universal Music Group’s Polygram Entertainment.

ABOUT POLYGRAM ENTERTAINMENT

Polygram Entertainment produces film and television programs that provide deeper narratives and perspectives on the recording artists, music and cultural events that came to define generations. A partner of Universal Music Group, the world leader in music-based entertainment, Polygram develops, produces, finances and distributes documentary features and original, scripted projects for music fans of all ages and tastes around the world.

Contact information

FOR MORE INFORMATION ON JONAS BROTHERS CONTACT:

Marisa Bianco // Republic Records
Marisa.Bianco@umusic.com

Alexis Rasten // Philymack
alexis@philymack.com

MEDIA CONTACT FOR AMAZON STUDIOS:
Alana Russo
alana.russo@amazonstudios.com

Brooke James
brooke.james@amazonstudios.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom